Health Canada
Symbol of the Government of Canada

Common menu bar links

Drugs and Health Products

Notice: Interim Policy on Health Canada's Interpretation of Medicinal Ingredient

June 16, 2015
Our file number: 15-107166-261

This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (that is, new drugs and abbreviated new drugs) of changes in Health Canada's interpretation of medicinal ingredient, and therefore to the assessment of pharmaceutical equivalence. The changes below form the basis of an interim policy, which Health Canada has implemented in view of a Federal Court decision (Justice Kane, 2013 FC 1217). The interim policy outlined herein supplements the existing Policy entitled, Interpretation of 'Identical Medicinal Ingredient' (2003). Taken together, the interim policy and the 2003 Policy will remain in effect while the matter is being fully considered and until further notice.

The changes do not apply to biological or radiopharmaceutical products, or to medicinal ingredients which do not possess a unique chemical structure [for example (e.g.), polymers with varying molecular weights].

Following the court's decision and for regulatory consistency, Health Canada  has reassessed its interpretation of "medicinal ingredient" as used in section C.01.004(1)(c)(iv) of the Food and Drug Regulations to mean the Active Pharmaceutical Ingredient (API) used as the raw material in the manufacture of the finished dosage form (FDF). As a result, drug labels must refer to the API as the medicinal ingredient. For drug products in which the medicinal ingredient undergoes a change in chemical form during the manufacturing process (e.g., in situ changes), the label should further indicate the chemical form in the FDF in brackets after the API. The source of the counter ion for a salt should not be listed as a non-medicinal ingredient.

Also, under the new interim policy, Health Canada will evaluate pharmaceutical equivalence between two drug products at the input stage (understood to mean the pharmaceutical equivalence of the APIs). However, when deciding whether the two medicinal ingredients are "identical", such that an Abbreviated New Drug Submission (ANDS) may be the appropriate route for assessment, Health Canada will also consider the manufacturing processes which can lead to variations in the chemical form of the medicinal ingredients in the FDF (e.g., in situ transformation of free base to salt). If the same medicinal ingredients at the input stage diverge into different forms, additional safety, effectiveness and quality data may be required. If the medicinal ingredients are different chemical forms at the input stage but nonetheless converge into the same chemical form, the medicinal ingredients will be considered "identical", and additional safety, effectiveness and quality data will not be required.

Further, the Patented Medicines (Notice of Compliance) Regulations will continue to apply where a comparison or reference is made to a drug found on the Patent Register, regardless of the question of equivalence. The application is not dependent on the determination of pharmaceutical equivalence. In addition, the established meaning of "claim for the medicinal ingredient" will continue to apply to the listing of patents on the Patent Register in accordance with section 4 of the Patented Medicines (Notice of Compliance) Regulations. Similarly, there is no impact on the application of the data protection provisions in section C.08.004.1 of the Food and Drug Regulations.

Submission sponsors are advised to discuss with Health Canada, in advance, when the "identicality" of two medicinal ingredients is in doubt for the purposes of establishing pharmaceutical equivalence.

  • For questions on pharmaceutical equivalence or labelling, please contact:
    • Bureau of Pharmaceutical Sciences
      Therapeutic Products Directorate
      Health Canada
      Finance Building
      Address Locator 0202A2
      Ottawa, Ontario
      K1A 1B9
    • Telephone: 613-941-3184
      Facsimile: 613-957-3989
      Email: bps_enquiries@hc-sc.gc.ca
  • For questions related to patent listings or data protection, please contact:
    • Office of Patented Medicines and Liaison
      Therapeutic Products Directorate
      Health Canada
      Finance Building
      101 Tunney's Pasture Driveway
      Address Locator 0201A1
      Ottawa, Ontario
      K1A 0K9
    • Telephone: 613-941-7281
      Facsimile: 613-946-5610
      E-mail: opml_bmbl@hc-sc.gc.ca